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INTRODUCTION 
The T S H response to intravenous T R H is well known to be abolished or 
markedly diminished in untreated hyperthyroidism [1,2]. However, the response 
of the hypophysis to T R H may be also inhibited in clinical situations where the 
patient is euthyroid as judged by Standard clinical and biochemical criteria, 
because of the extreme sensitivity of the pituitary cell to thyroid hormones [3]. 
This Situation is seen frequently in patients with autonomous nodules, but could 
also occur in patients with diffuse or nodular goiters [4-8]. In addition, other 
conditions have been described with impaired T S H response to intravenous T R H 
despite euthyroid function [9,10]. 
Therefore, a negative intravenous T R H test in euthyroid patients is not neces-
sarily associated with early thyroid autonomy. 
In our study we compared first clinical and scintigraphic findings in patients 
with suggested early thyroid autonomy and euthyroid controls. Patients with no 
scintigraphic evidence of autonomous thyroid nodules were further investigated 
by oral T R H Stimulation, which seemed to be useful in the evaluation of patients 
with impaired T S H reserve but euthyroid function [11-13]. In addition, we in-
vestigated, if there were significant differences of parameters of thyroid function 
in these patients in comparison to euthyroid controls. 
MATERIALS AND METHODS 
The study included a total of 815 outpatients (208 males and 607 females) with 
an age ränge of 16-72 years. They attended our clinic with the suspicion of 
thyrometabolic dysfunction. In all of these patients T 4 and T 3 determinations and 
Standard 200 p g T R H tests had been performed. 705 of these patients were clinical 
euthyroid and revealed normal or borderline levels of T 4 and T 3 . Only these 
patients were further evaluated. 
HORMONE ASSAYS 
T S H was measured by radioimmunoassay with use of kits obtained from 
Henning, Berlin, F.R.G. The reference ränge for basal T S H of euthyroid subjects 
was found to be 0.7-3.2 /juV/ml (5-95%), mean 1.6/iU/ml. The reference ränge of 
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T S H 30 min after the application of 200 /xg T R H was 2.3-21.8 fiü/ml (5-95%), 
mean 10.9 /xU/ml. T 4 was measured by enzymeimmunoassay with the use of kits 
from S Y V A Company, Palo Alto, USA. Reference ränge was found to be 3.8-
10.6 Mg/dl ( x ± 2 S.D.), mean 7.2 / x g / d l . T 3 was determined by radioimmunoassay, 
kits were obtained from Amersham-Buchler, Braunschweig, F.R.G. Reference 
ränge was calculated to be 0.9-2.5 ng/ml (je ± 2 S.D.), mean 1.7 ng/ml. Free T 4 was 
measured by radioimmunoassay with use of kits from Corning Medical, Medfield, 
USA. The reference ränge was determined to be 0.8-2.2ng/dl (x±2 S.D.), mean 
1.5 ng/dl. TBI was determined by enzymeimmunoassay test kit TBK> Boehringer 
Mannheim, F.R.G. Reference ränge of FT 4 I = T 4 /TBI was found to be 1.5-10.3 
(x±2 S.D.), mean 5.9. Radioimmunoassay of T B G were performed with kits 
obtained from Henning, Berlin, F.R.G. Reference ränge of T4/TBG was calculated to 
be 1.8-6.2 (de ± 2 S.D.), mean 4.0. 
E x p e r i m e n t a l D e s i g n 
Intravenous T R H tests were performed after an overnight fast with a bolus-like 
injection of 200 / x g T R H (Hoechst). T S H levels were determined at 0 and 30 min. 
For oral T R H tests a 40 mg tablet of T R H (Thyroliberin Merck) was used. T S H 
levels were determined at 0, 60, 120, 180 and 240 min. There was an interval of 
2-6 weeks between the intravenous and oral T R H tests. Statistical analysis were 
carried out by use of the Wilcoxon test. 
RESULTS 
Ninty-nine of the 705 clinical euthyroid patients showed a negative or sub-
normal i.v. T R H test. The clinical and scintigraphic findings of these patients in 
comparison to the euthyroid controls with normal i.v. T R H test are shown in Table 
I. In 28% of patients with negative or subnormal i.v. T R H tests autonomous 
thyroid nodules were detected in comparison to only 1% in the euthyroid control 
group. Patients with suggested thyroid autonomy showed a normal thyroid gland 
in 26%, a diffuse goiter in 22%, a nodular goiter in 22%; in euthyroid controls 
thyroid gland was normal in 52%, in 22% a diffuse and in 16% a nodular goiter 
was found. Patients with scintigraphic established thyroid autonomy were not 
further investigated. To evaluate the possibility of insufficient T R H Stimulation in 
the other patients with negative or subnormal i.v. T R H tests a prolonged Stimula-
tion with 40 mg T R H given orally was performed. Forty-two of the total of 71 
TABLE I 
CLINICAL AND SCINTIGRAPHIC FINDINGS IN 99 PATIENTS WITH SUGGESTED EARLY 
THYROID AUTONOMY AND 606 EUTHYROID CONTROLS 
Diagnosis e.t.a. (%) e.c. (%) 
Normal thyroid gland 26 51.7 
Diffuse goiter I-IH 22 23 
Nodular goiter I-IH 22 16 
Comp, autonomous adenoma 14 1 
Dec. autonomous adenoma 14 0.3 
Part. res. goiter 2 8 
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patients could be reinvestigated. A selective T S H response to oral T R H application 
with a A T S H > 2.1 /xU/ml was found in 24 patients 180 min after the application 
of the releasing hormone (Fig. 1). Mean maximum T S H values were usually 
obtained at 180 min, but positive T S H Stimulation was present between 120 and 
240 min in all of these cases (Fig. 2). The 24 patients with selective response of 
T S H to oral T R H showed normal concentrations of T 4 and T 3 . 
The 18 patients with negative or subnormal oral T R H tests revealed normal 
values of T 4 , T 3 concentra^k ns were normal in 14 and only slightly elevated in 4 
cases (Fig. 3). However, Statistical analysis demonstrated significant differences of 
mean values for T 3 (2a < 0.001) and even for T 4 (2a < 0.005) between these groups 
(Table II). In addition to evaluate the possible influence of free thyroxine concen-
trations T ^ T B G , free thyroxine index (FT4I) and free thyroxine (f-T4) were 
measured. In patients with selective response of T S H to oral T R H these 
Parameters were within the normal ränge and not significantly different from 
euthyroid controls with normal i.v. T R H tests in accordance with euthyroidism 
(Table II). Patients with failing or impaired response of T S H to oral T R H 
Stimulation showed significant higher values of T ^ T B G (2a < 0.005), free thy-
roxine index (2a < 0.001), and free T 4 (2a < 0.005) suggesting early thyroid 
autonomy (Table H). 
To investigate the possible presence of cardiovascular effects of thyroid hor-
mones in these patients we measured the Q-Kd interval, which means timing of 
Korotkoff arterial sounds with reference to the electrocardiogram [19-21]. Car-
diovascular effects of thyroid hormones could not be completely excluded in 
patients with absent or impaired response to oral T R H but seemed to be unlikely 
in patients with positive oral T R H Stimulation tests (Table IQ). 
TSH/uU/ml 
50 
2.0-
1.5 
1,0 • 
TSH 30 min TSH 180 min 
(i.v.TRH ) (oral TRH) 
Fig. 1. Comparison of TSH values in 42 patients with failing or subnormal response 30 min after i.v. 
TRH and 180 min after oral TRH application. 
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TSH 
/uU/ml 
Fig. 2. TSH values in 24 patients with selective response to oral TRH 60, 120, 180 and 240 min after 
the application of the releasing hormone. 
Clinical examination of the thyroid gland in the 24 patients with selective T S H 
response to oral T R H revealed a normal gland in 3 cases, a diffuse goiter in 12 and 
a nodular goiter in 9 cases. The 18 patients with failing response of T S H to oral T R H 
showed a normal thyroid gland in 2, a diffuse goiter in 8 and a nodular goiter in 8 
cases. 
T3 ng/ml 
o • 
• • o 
o» • o • • • •<> o o o • o o o o o o o o • o o o o 
0 4 — i — — i 1 1 1 1 1 1 1 |l * 
0 1 2 3 4 5 6 7 8 9 10 T 4 /ug/100 ml 
Fig. 3. Correlation of T 4 and T 3 in 24 patients O with selective TSH response to oral TRH and 18 
patients • with failing or subnormal response of TSH to oral TRH. 
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TABLE H 
PARAMETERS OF THYROID FUNCTION IN THE 24 PATIENTS WITH SELECTIVE RESPONSE 
OF TSH TO ORAL TRH AND THE 18 PATIENTS WITH FAILING RESPONSE OF TSH TO ORAL 
TRH 
Selective response Failing response 
T 4 6.9 ±1 .5 /xg/dl 7.9 ±0.9/ig/dl 
T 3 1.5 ±0 .4 ng/ml 2.1 ±0 .4 ng/ml 
T4 /TBG 3.8 ±1 .1 4.7 ±1.5 
F T J 5.9 ±2 .2 7.9 ±2 .2 
f-T4 1.5 ± 0 . 4 ng/dl 1.9 ±0.5 ng/dl 
These findings demonstrate that thyroid autonomy could occur not only in 
multinodular goiter but also in diffuse goiter and even in patients with normal 
thyroid gland. 
DISCUSSION 
The availability of synthetic T R H for clinical use led to detailed investigation of 
the interaction between T R H and the thyroid hormones at the level of the 
pituitary cells, which respond extremely sensitive to small excess of circulating 
thyroid hormone concentration [14-18]. Therefore, impaired or failing response of 
T S H to intravenous T R H is highly sensitive for detecting early thyroid autonomy. 
In our study about 14% of all apparently euthyroid patients revealed negative or 
subnormal intravenous T R H tests. In approximately 1/3 of these autonomous 
thyroid nodules were present. These findings underline that the i.v. T R H test is of 
considerable value in the detection of autonomous thyroid nodules in the absence 
of clinical signs or elevated thyroid hormones. However about 2/3 of the patients 
with impaired or absent response to i.v. T R H showed no scintigraphic evidence of 
autonomous thyroid regions. To evaluate the possibility of insufficient T R H Sti-
mulation a prolonged T R H test with 40 mg T R H given orally was performed, 
which led in about 60% to positive T S H Stimulation. The oral T R H test seemed to 
be capable to divide patients with failing or impaired response to i.v. T R H in a 
group of low responders' and a group with early thyroid autonomy in accordance 
with findings of Staub et al. [12,13]. In Single cases stimulated T S H values 
reached a maximum of 36 //,U/ml. The different effects of oral T R H in comparison 
TABLE m 
Q-Kd INTERVAL IN THE 24 PATIENTS WITH SELECTIVE RESPONSE OF TSH TO ORAL TRH 
AND THE 18 PATIENTS WITH FAILING RESPONSE OF TSH TO ORAL TRH IN COMPARISON 
TO EUTHYROID AND HYPERTHYROID CONTROLS 
Q-Kd ms 
Euthyroidism 217.3 ±12.9 
Selective response 210.4 ±11.6 
Failing response 200.2 ±11.4 
Hyperthyroidism 168.8 ±16.6 
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to intravenous T R H are most likely due to the prolonged Stimulation and not 
dependent from the different dosage, since similar T S H stimulations were seen 
after a 2 h infusion with 200 p g T R H . Positive T S H Stimulation by oral T R H has 
not been observed in patients with T 3 concentrations above 3 ng/ml. In view of these 
results the oral T R H test seemed to be superior to the i.v. T R H test in differen-
tiating euthyroidism from early thyroid autonomy. Therefore, for further 
Classification of patients with absent or impaired response to i.v. T R H subsequent 
to scintigraphic studies an oral T R H test is recommended, if levels of thyroid 
hormones were normal or borderline. 
In patients with negative or subnormal oral T R H tests early thyroid autonomy 
is likely to be present because of significant higher concentrations of thyroid 
hormones including free thyroxine. However, these results demonstrate that the 
determination of free thyroxine, T 4 / T B G and free thyroxine index is not superior to 
the determination of thyroxine alone. A l l these parameters, including the deter-
mination of T 3 , are not able to differentiate euthyroidism from early thyroid 
autonomy. Therefore, the value of free thyroxine, T 4 / T B G and free thyroxine index 
(F-T4I) in the routine diagnosis of thyroid function is only limited. Cardiovascular 
effects of thyroid hormones could not be completely excluded in patients with 
absent or impaired response to oral T R H but seemed to be unlikely in patients 
with positive oral T R H Stimulation tests. 
It is concluded that the oral T R H test is useful for the evaluation of patients 
with impaired T S H reserve. A normal response to oral T R H provides strong 
evidence of euthyroid function. Patients with failing response to oral T R H deserve 
further investigation and follow-up, since T S H suppression due to early thyroid 
autonomy is likely to be present. 
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DISCUSSION 
Elte: (Leiden) Do you think that your results with the i.v. and the oral TRH-test point to a graded 
autonomy? 
Jüngst: (Munich) I can only speculate on this, but we have found no differences in mean concentrations 
of thyroid hormones between euthyroid controls with normal i.v. TRH-tests and patients with normal 
response of TSH to oral TRH but negative i.v. TRH-tests. Negative i.v. TRH-tests in these patients are 
most likely caused by insufficient Stimulation, since a prolonged application of 200 mcg TRH in-
travenously is as effective as 40 mg TRH given orally. These findings would point against a graded 
autonomy. However, we were surprised about the high rate of scintigraphic autonomy in our patients with 
negative or subnormal i.v. TRH-tests and I suppose if we had primarily performed the oral TRH-test, the 
number of detected patients with scintigraphic autonomy would be smaller. Therefore, I think that the i.v. 
TRH-test is the most sensitive parameter in the detection of thyroid autonomy. 
Crooks: (Dundee) In the case of the oral TRH-test, how do you ensure that the patient actually takes the 
drug, since non-compliance with oral drug-taking is a universal problem? This will present considerable 
difficulties of interpretation in the case of non-responders to oral TRH. 
Jüngst: (Munich) I don't think that the non-responders had failed to take the drug, since in our study 
each patient took the tablet in the clinic. Measurements of thyroid hormones showed small elevations, 
especially of T 3 , which is most likely due to early thyroid autonomy. However, in outpatients testing, this 
may play an important part in false negative results. Therefore, we would not recommend performing the 
oral TRH-test in the diagnosis of thyroid function primarily; this test is reserved for special cases only. 
